Detalhe da pesquisa
1.
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial.
Lancet HIV
; 10(12): e767-e778, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37952550